OBJECTIVE: The aim of this study was to evaluate the effect of sampling duration on pharmacokinetic parameters from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and their diagnostic accuracy regarding the detection of potentially malignant prostate lesions. MATERIALS AND METHODS: Sixty-six consecutive male patients (mean [SD] age, 65.4 [10.8] years) with clinically suspected prostate cancer were included. All patients underwent multiparametric MRI of the prostate (T2-weighted imaging, diffusion-weighted imaging, and DCE-MRI) on a 3 T MRI scanner. Patients were divided into 2 groups depending on the prostate imaging reporting and data system (PI-RADS) score of the detected lesions (group A: PI-RADS ≤3, n = 32; group B: PI-RADS >3, n = 34). In all patients, DCE-MRI was performed using a CAIPIRINHA-Dixon-TWIST volume interpolated breath-hold examination sequence (spatial resolution, 3 × 1.2 × 1.2 mm; temporal resolution, 5 seconds; total sampling duration, 4:10 minutes [250 seconds]) with body weight-adapted administration of contrast agent (gadobutrol, Bayer Healthcare, Berlin, Germany). Five DCE-MRI series with different acquisition durations ranging from 50 to 250 seconds were retrospectively generated from the original data sets. Pharmacokinetic parameters (ie, Ktrans, Kep, Ve, and iAUC60) were calculated for the different sampling durations using the Tofts model. Both lesion groups and all 5 DCE-MRI series were compared regarding pharmacokinetic parameters. Diagnostic accuracy for the detection of potentially malignant lesions was calculated for all 5 series using receiver operating characteristic analysis. RESULTS: For all 5 series, Ktrans, Kep, and iAUC60 in patient group B were significantly higher than the respective parameters in patient group A (all P ≤ 0.008). In both groups, Ktrans, Kep, and iAUC60 remained constant at 200 and 150 seconds acquisition duration and did not significantly differ from parameters estimated from the original data sets (250 seconds; all P ≥ 0.310). Ve did not differ significantly between the 2 groups (P ≥ 0.337) and acquisition time did not have a significant effect on this parameter (P ≥ 0.275). Receiver operating characteristic analyses showed consistent diagnostic accuracy for the different series; only diagnostic accuracy of Kep decreased with lowered sampling duration, showing lowest accuracy for the 50-second series (0.682; 95% confidence interval, 0.553-0.811). CONCLUSIONS: Using fast optimized DCE-MRI of the prostate, a minimum sampling duration of 150 seconds is required for sufficient pharmacokinetic parameter estimates, providing a high diagnostic accuracy regarding the discrimination between benign and potentially malignant lesions.
OBJECTIVE: The aim of this study was to evaluate the effect of sampling duration on pharmacokinetic parameters from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and their diagnostic accuracy regarding the detection of potentially malignant prostate lesions. MATERIALS AND METHODS: Sixty-six consecutive male patients (mean [SD] age, 65.4 [10.8] years) with clinically suspected prostate cancer were included. All patients underwent multiparametric MRI of the prostate (T2-weighted imaging, diffusion-weighted imaging, and DCE-MRI) on a 3 T MRI scanner. Patients were divided into 2 groups depending on the prostate imaging reporting and data system (PI-RADS) score of the detected lesions (group A: PI-RADS ≤3, n = 32; group B: PI-RADS >3, n = 34). In all patients, DCE-MRI was performed using a CAIPIRINHA-Dixon-TWIST volume interpolated breath-hold examination sequence (spatial resolution, 3 × 1.2 × 1.2 mm; temporal resolution, 5 seconds; total sampling duration, 4:10 minutes [250 seconds]) with body weight-adapted administration of contrast agent (gadobutrol, Bayer Healthcare, Berlin, Germany). Five DCE-MRI series with different acquisition durations ranging from 50 to 250 seconds were retrospectively generated from the original data sets. Pharmacokinetic parameters (ie, Ktrans, Kep, Ve, and iAUC60) were calculated for the different sampling durations using the Tofts model. Both lesion groups and all 5 DCE-MRI series were compared regarding pharmacokinetic parameters. Diagnostic accuracy for the detection of potentially malignant lesions was calculated for all 5 series using receiver operating characteristic analysis. RESULTS: For all 5 series, Ktrans, Kep, and iAUC60 in patient group B were significantly higher than the respective parameters in patient group A (all P ≤ 0.008). In both groups, Ktrans, Kep, and iAUC60 remained constant at 200 and 150 seconds acquisition duration and did not significantly differ from parameters estimated from the original data sets (250 seconds; all P ≥ 0.310). Ve did not differ significantly between the 2 groups (P ≥ 0.337) and acquisition time did not have a significant effect on this parameter (P ≥ 0.275). Receiver operating characteristic analyses showed consistent diagnostic accuracy for the different series; only diagnostic accuracy of Kep decreased with lowered sampling duration, showing lowest accuracy for the 50-second series (0.682; 95% confidence interval, 0.553-0.811). CONCLUSIONS: Using fast optimized DCE-MRI of the prostate, a minimum sampling duration of 150 seconds is required for sufficient pharmacokinetic parameter estimates, providing a high diagnostic accuracy regarding the discrimination between benign and potentially malignant lesions.
Authors: Silvin Paul Knight; Jacinta Elizabeth Browne; James Frances Mary Meaney; Andrew John Fagan Journal: MAGMA Date: 2017-04-10 Impact factor: 2.310
Authors: Nestor Andres Parra; Alan Pollack; Felix M Chinea; Matthew C Abramowitz; Brian Marples; Felipe Munera; Rosa Castillo; Oleksandr N Kryvenko; Sanoj Punnen; Radka Stoyanova Journal: Front Oncol Date: 2017-11-10 Impact factor: 6.244
Authors: Elizabeth Rourke; Abhijit Sunnapwar; Daniel Mais; Vishal Kukkar; John DiGiovanni; Dharam Kaushik; Michael A Liss Journal: Investig Clin Urol Date: 2019-07-30